The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Hyperammonemia in cirrhosis induces transcriptional regulation of myostatin by an NF-κB–mediated mechanism
Open accessAbstract
Significance: Loss of skeletal muscle mass, or sarcopenia, is nearly universal in cirrhosis and adversely affects the outcome of these patients. There are no established therapies to prevent or reverse sarcopenia because the mechanisms are not known. We show that the expression of myostatin, a negative regulator of skeletal muscle mass, is increased in the cirrhotic muscle and is mediated by increased ammonia concentration. Skeletal muscle ammonia concentrations are significantly increased in cirrhosis, resulting in activation of the transcription factor NF-κB, which in turn increases the expression of myostatin. Given the high prevalence of cirrhosis, these studies are of broad general interest because ammonia-lowering strategies, NF-κB antagonists, and myostatin blocker are potential therapies to reverse sarcopenia of cirrhosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Myostatin, a Negative Regulator of Muscle Growth, Functions by Inhibiting Myoblast Proliferation
Thomas, M., Langley, B., Berry, C., Sharma, M., Kirk, S., Bass, J., & Kambadur, R. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004356200 · Cited by 1,014
Muscle Wasting Is Associated With Mortality in Patients With Cirrhosis
Montano–Loza, A. J., Meza–Junco, J., Prado, C. M. M., Lieffers, J. R., Baracos, V. E., Bain, V. G., & Sawyer, M. B. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.08.028 · Cited by 810
Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size
Trendelenburg, A. U., Meyer, A., Rohner, D., Boyle, J., Hatakeyama, S., & Glass, D. J. (2009) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00105.2009 · Cited by 792
Myostatin negatively regulates satellite cell activation and self-renewal
McCroskery, S., Thomas, M., Maxwell, L., Sharma, M., & Kambadur, R. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200207056 · Cited by 784
McFarlane, C., Plummer, E., Thomas, M., Hennebry, A., Ashby, M., Ling, N., Smith, H., Sharma, M., & Kambadur, R. (2006) · Journal of Cellular Physiology · doi:10.1002/jcp.20757 · Cited by 480
Myostatin inhibits cell proliferation and protein synthesis in C2C12 muscle cells
Taylor, W. E., Bhasin, S., Artaza, J., Byhower, F., Azam, M., Willard, D. H., Kull, F. C., & Gonzalez-Cadavid, N. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.280.2.e221 · Cited by 410
The dynamics of ammonia metabolism in man. Effects of liver disease and hyperammonemia.
Lockwood, A. H., McDonald, J. M., Reiman, R. E., Gelbard, A. S., Laughlin, J. S., Duffy, T. E., & Plum, F. (1979) · Journal of Clinical Investigation · doi:10.1172/jci109322 · Cited by 405
The role of myostatin in muscle wasting: an overview
Elkina, Y., von Haehling, S., Anker, S. D., & Springer, J. (2011) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1007/s13539-011-0035-5 · Cited by 348
Amirouche, A., Durieux, A.-C., Banzet, S., Koulmann, N., Bonnefoy, R., Mouret, C., Bigard, X., Peinnequin, A., & Freyssenet, D. (2009) · Endocrinology · doi:10.1210/en.2008-0959 · Cited by 282
Periyalwar, P., & Dasarathy, S. (2012) · Clinics in Liver Disease · doi:10.1016/j.cld.2011.12.009 · Cited by 249
Self-citation
Cited by
EASL Clinical Practice Guidelines on nutrition in chronic liver disease
Merli, M., Berzigotti, A., Zelber-Sagi, S., Dasarathy, S., Montagnese, S., Genton, L., Plauth, M., & Parés, A. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.06.024 · Cited by 1,130
Self-citationNishikawa, H., Shiraki, M., Hiramatsu, A., Moriya, K., Hino, K., & Nishiguchi, S. (2016) · Hepatology Research · doi:10.1111/hepr.12774 · Cited by 656
Sarcopenia from mechanism to diagnosis and treatment in liver disease
Dasarathy, S., & Merli, M. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.07.040 · Cited by 608
Self-citationSarcopenia and frailty in decompensated cirrhosis
Tandon, P., Montano-Loza, A. J., Lai, J. C., Dasarathy, S., & Merli, M. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.01.025 · Cited by 408
Self-citationSinclair, M., Gow, P. J., Grossmann, M., & Angus, P. W. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13549 · Cited by 316
Metadata
- Authors
- Qiu, J., Thapaliya, S., Runkana, A., Yang, Y., Tsien, C., Mohan, M. L., Narayanan, A., Eghtesad, B., Mozdziak, P. E., McDonald, C., Stark, G. R., Welle, S., Naga Prasad, S. V., & Dasarathy, S.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2013-10-21
- Volume
- 110
- Issue
- 45
- Pages
- 18162-18167
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2127764242
- Cited by
- 292
- References
- 38
- FWCI
- 4.71
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hyperammonemia in cirrhosis induces transcriptional regulation of myostatin by an NF-κB–mediated mechanism. https://app.cochat.ai/papers/10.1073/pnas.1317049110
- The paper
- Qiu, J., Thapaliya, S., Runkana, A., Yang, Y., Tsien, C., Mohan, M. L., Narayanan, A., Eghtesad, B., Mozdziak, P. E., McDonald, C., Stark, G. R., Welle, S., Naga Prasad, S. V., & Dasarathy, S. (2013). Hyperammonemia in cirrhosis induces transcriptional regulation of myostatin by an NF-κB–mediated mechanism. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1317049110
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.